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Abstract 
Background: During the last decade, the number of clinical trials conducted in sub-Saharan Africa has increased sig-
nificantly which has helped to address priority health problems in the region. Navrongo health research centre since 
it was established in 1989, has conducted several trial studies including rectal artesunate trial in the Kassena-Nankana 
districts. However, there is little evidence-based for assessing the impact of new drug trials. This study explored factors 
that motivate parents to allow their children to participate in new drug trials in northern Ghana.
Method: The study used both quantitative and qualitative methods. The participants were randomly selected 
from among parents whose children were enrolled in a new drug trial conducted in the Kassena-Nankana districts 
between 2000 and 2003. QSR Nvivo 9 software was used to code the qualitative data into themes before analysis 
while STATA software Version 11.2© was used to analyze the quantitative data.
Results: The results showed that majority (95.9 %) of the parents were willing to allow their children to be enrolled 
in future new drug trials. The main factors motivating their willingness to allow their children to be enrolled in these 
trials were quality of health care services offered to trial participants (92.9 %), detail medical examination (90.8 %), 
promptness of care provided (94.4 %) and quality of drugs (91.9 %). Other factors mentioned included disease preven-
tion (99.5 %) and improved living standard (96.1 %). Parents reported that the conduct of these trials had reduced the 
frequency of disease occurrences in the communities because of the quality of health care services provided to the 
children recruited into these trial studies.
Conclusion: Though the implementation of clinical trials in the study area is believed to have positive impact on 
health status of people particularly trial participants, measures should however be taken to address safety and likely 
side effects of new drugs given to trial participants during these trial studies.
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Background
During the last decade, the number of clinical trials con-
ducted in sub-Saharan Africa has increased significantly. 
This has led to the creation of new funding mechanisms 
for clinical research which has helped to address priority 
health problems in the region [1]. Clinical trials research 
before the year 2000 was mainly carried out in affluent 
countries with the sponsorship and funding from phar-
maceutical industry. Today trial studies are also carried 
out in resource-constrained contexts, and they are often 
sponsored by academic or not-for-profit organizations 
with some being funded externally. Reliable evidence is 
essential to improve health care delivery and to support 
efficient use of limited resources. Randomized clinical 
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trials (RCTs) are the most rigorous method of generat-
ing information to help patients, clinicians, policy-mak-
ers and funding agencies make informed clinical and 
health policy decisions. Without this evidence, there is a 
risk that people could be given treatments that might be 
harmful to them [2]. Evidence exists that clinical trials are 
conducted to test the efficacy and safety of new drugs and 
this allows researchers to come out with new drugs for 
the treatment of certain diseases in communities [2–4].
It is established that about 62  % of trials participants 
had no knowledge on the conduct of new drug trials [5]. 
This could be attributed to poor sensitization and educa-
tion prior to new drug trial implementation. It might also 
be blamed on poor consenting before trial participants 
take a decision to participate in these trials [6–8]. It has 
also been established that misconceptions about the use 
of samples affects recruitment and retention of partici-
pants into trial studies [9, 10]. There are certain risks that 
trials participants are exposed to when they take part in 
these trial studies. Trials participants are not sure of the 
efficacy and side effects of these new drugs they receive 
[4, 11]. Other risks such as getting infected with virus, 
worsening of health status, damage to the liver and kid-
ney have also been mentioned as likely risks associated 
to new drug trials [3]. It is demonstrated that trial par-
ticipants felt they were being used as guinea pigs because 
of the placebo participants received during these tri-
als [2, 3]. The conduct of clinical trials in Sub-Saharan 
Africa has significantly increased over the years. There-
fore, there is the need to examine these challenges more 
closely and also document the impact of the conduct of 
these trials to participants and their families.
Navrongo health research centre (NHRC) located in 
central Navrongo was establishment in 1989 with the 
mandate of conducting high quality demographic and 
health research to inform policy. The research centre 
started with vitamin A supplementation trial (VAST) 
study which was conducted to assess the impact on child-
hood morbidity and mortality in northern Ghana [12]. 
The trial made a huge impact in the study communities 
and because of that the term VAST has been used syn-
onymously with the research centre by community mem-
bers. The centre over the years has conducted several 
other trial studies including rectal artesunate trial in the 
study area. The artesunate trial was conducted from 2000 
to 2004 with a little over 2000 children enrolled into the 
study. The trial was both community and facility-based, 
and had over 45 fieldworkers and supervisors living in 
the communities to recruit cases into the study [13]. 
However, there is little evidence-based for assessing the 
impact of these trials on communities where these tri-
als take place especially people who are recruited into 
these trials. Little evidence also exists in determining the 
attitude and willingness of people to participate in new 
drug trial studies. This study was designed to explore fac-
tors that motivate parents to allow their children to par-
ticipate in these trials in the Kassena-Nankana districts 
of northern Ghana.
Methods
Study design
The study used mixed method where both quantitative 
and qualitative techniques were used for data collection. 
The quantitative survey presents figures and percent-
ages on research problem whilst qualitative interviews 
encouraged people to explain in more detail their per-
sonal opinions and experiences on the problem under 
investigation. Both interviews were conducted with par-
ents whose children were recruited into rectal artesunate 
trial and other trials conducted in the study area. The 
qualitative component of the study was done first and 
issues that came up in the data informed the study team 
on the type of questions to be asked in the survey. This 
was to enable the study investigators to test the signifi-
cant of these issues quantitatively.
Study site
The study was conducted in the Kassena-Nankana east 
and west districts (KNEWDs) of northern Ghana. The 
area shares borders with Burkina Faso in the north and 
covers an area of about 1675 km2 and an estimated popu-
lation of approximately 152,000 under surveillance by 
the Navrongo health demographic surveillance system 
(NHDSS) [14] operating under the NHRC. The districts 
have two distinct seasons, a wet season that runs from 
May to September and a long dry season from October 
to April with hardly any rains. There are two main ethnic 
groups in the area, the Kasenas and the Nankani speak-
ing people.
The districts have five health centers, two clinics, and 
27 functional Community-based health planning and 
services (CHPS) compounds located in various villages 
with resident community health officers (CHOs) offer-
ing doorstep health care services to the people [15, 16]. 
The main referral hospital (War Memorial Hospital) is 
located at the capital (Navrongo town) of the KNED.
Sample size calculation
We aimed to interview 380 randomly-sampled parents 
whose children were recruited into rectal artesunate trial. 
This was based on the assumption that we would be able 
to estimate the acceptability of new drug trials within a 
margin of error of 5 %, at 95 % confidence level. Given the 
length of time between the time the trial was conducted 
and the time of the current survey, we allowed for a 20 % 
rate of non-responders.
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Sampling technique
The NHRC operates a demographic surveillance sys-
tem (NDSS) in the Kassena-Nankana east and west dis-
tricts. The districts have been divided into five zones 
(north, south, east, west and central) [14]. Each zone is 
sub divided into clusters/communities and further into 
compounds. There are about 270 clusters and 17, 855 
compounds that have been enumerated and given com-
pound numbers (COMPOUND IDs). Members in each 
compound are given unique identity numbers (PERMA-
NENT IDs) for easy identification, and information on 
births, pregnancies and other vital demographic events 
are collected and updated at every 120 days interval [14]. 
The interviews were conducted in three zones (north, 
south and central) in the two districts. A cluster sampling 
technique was used in this study. Simple random sam-
pling technique was used to select two zones (north and 
south) and central zone which is located in the central 
Navrongo was automatically selected.
Simple random sampling technique was used to select 
from among parents whose children were enrolled in 
the artesunate trial which was conducted in the districts 
between 2000 and 2003 (ISRCTN46343627). The trial 
was randomized-controlled study that assessed the effi-
cacy of using rectal artesunate pre-referral medication. 
The trail was conducted to assess the effect of the artesu-
nate medication on child mortality in the districts [13]. 
The selection was done proportionately to the popula-
tion or number of artesunate trial participants who were 
recruited into the trial in each of the three zones taking 
into consideration the total sample size for the study. 
Twenty percent was used to select additional list in each 
of the zones to take care of respondents who were likely 
not to be available at the time the interviews were con-
ducted. Rectal artesunate trial participants were selected 
because there existed a database of the parents of chil-
dren enrolled in the study.
Since this trial ended in 2003 and a number of other 
trials have taken place in the study area that targeted 
children in the same age band, it is conceivable that the 
participants sampled in this study may have had experi-
ence from other trials. We therefore anticipated that their 
views on clinical trials as expressed in this study could 
not be solely attributed to their experience during the 
index trial. Simple random sampling method was also 
used to select respondents for the in-depth interviews. 
Using a list of children who participated in the artesu-
nate trial as the sample frame, potential participants in 
this study were randomly selected in all the zones and a 
list generated for the In-depth interviews. The principle 
of saturation was used where the data collection, pro-
cessing and analysis were done concurrently until no 
new information was obtained. A total of 80 in-depth 
interviews were conducted with parents whose children 
were recruited into rectal artesunate trial.
Data collection technique and tools
A structured survey questionnaire was used to interview 
respondents. The potential respondents selected were 
followed up by trained data collectors using respondents’ 
background information such as name of study child, 
name of mother, compound name, compound ID, cluster 
ID and name of village. The data collectors visited poten-
tial study participants and those who granted consent 
were interviewed. The interviews were conducted until 
the sample size of 380 was achieved.
Interview guide was used to conduct the in-depth 
interviews with parents. Interview moderators were 
assigned to the various zones and potential participants 
contacted to establish their availability and willingness to 
be interviewed. After obtaining consent from study par-
ticipants, suitable arrangements were made for the inter-
views to be conducted at home.
Training of data collectors
Senior high school graduates were recruited and trained 
for the quantitative data collection whilst first degree 
graduates with experience in qualitative interview mod-
eration were recruited and trained to conduct the in-
depth interviews. The training for both groups lasted for 
1 week and covered areas such as the purpose and objec-
tives of the study, quantitative and qualitative data collec-
tion techniques, how to obtain informed consent from 
study participants and translation of the questionnaire 
into the various local languages used in the study area 
(Kasem and Nankam). Role-play was done by all the data 
collectors to help them have a better understanding of 
how to ask the questions appropriately during the actual 
data collection. The questionnaire and the guides were 
both pre-tested which enabled the study team to finalize 
them for the actual interviews.
Supervision was very key to the successes of the study. 
Therefore, at each stage of the data collection, the data 
collectors were supervised by a field supervisor to make 
sure that the data collection was done accurately. All 
completed questionnaires were checked by the field 
supervision to resolve all queries. All questionnaires with 
problems were given back to the data collectors responsi-
ble to go back to the field and resolve such issues before 
the forms were submitted for data entry.
Data processing and analysis
The quantitative survey data was double-entered and veri-
fied using Epidata 3.1 with built in consistency checks to 
control data input. Data cleaning by way of identifying out-
liers and checking for consistencies among variables were 
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carried out by running frequencies and cross tabulations 
using STATA software Version 11.2©. Descriptive analyses 
were used to describe socio-demographic characteristics of 
respondents. The statistical point estimates were computed 
and presented as percentages for all the background char-
acteristics and views on factors that influence community 
members’ willingness to participant in clinical trials.
The qualitative interviews were tape recorded and 
transcribed verbatim and entered into a computer using 
Microsoft word. A coding list was prepared to guide the 
data coding and analysis. Data was organized using QSR 
Nvivo 9 software before analysis. The data was coded twice 
where the first coding was used to code the data into major 
themes while the second coding was used to further code 
the data into more specific sub-themes. The data analysis 
was going on simultaneously with data collection. This was 
to make sure that information was collected to cover all 
the themes. Codebook was developed based on the major 
themes of the study and transformed into tree notes and 
free notes. Common themes were highlighted and quotes 
were selected and used to support themes in the results.
Ethical considerations
Ethical approval for the study was received from the 
NHRC institutional review board (IRB). Written 
informed consent was obtained before the interviews 
were conducted. The data collectors read and translated 
the consent forms into the preferred local language of 
the participants. All participants were informed before 
the start of the interview about project goals, how long 
the interview would last, their right to refuse being inter-
viewed, right to withdraw in the process of the interview 
and about the intended use of the results for scientific 
publications and also disseminate the findings to stake-
holders. To ensure confidentiality, identification numbers 
were assigned to participants in the qualitative interviews 
instead of their names.
Results
Socio‑demographic characteristics of respondents
The results showed that majority of the respondents 
88.6 % (349) were females whilst most of the participants 
56.4 % (222) fell between the ages of 31 and 44. From the 
results, 64.5  % (254) of respondents never had formal 
education while only about 0.5 % (2) went up to Tertiary/
higher level. The results showed that more than half of 
the respondents (60.4  %) were subsistent farmers with 
only 1 % (4) of them being civil/public servants (Table 1).
Parents expectations before allowing their children to take 
part in these trials
Most of the parents reported that what they expected 
before allowing their children to be enrolled in these new 
drug trial studies was achieved. They mentioned good 
health for their children as the main thing they expected. 
They were of the view that their participation in these 
studies made them to get good health care, good drugs 
and appropriate attention and treatment for their chil-
dren and that ensured their good health. Others were of 
the opinion that they wanted their children to be taken 
care of fully including payment of their hospital bills by 
trial studies and that necessitated their involvement in 
these trial studies. Few other parents reported that they 
wanted to receive health education on how to take proper 
Table 1 Socio Demographic Characteristics of  Respond-
ents
Variables N = 394 frequency Percentage
Age of respondent
 18–30 50 12.7
 31–44 222 56.4
 45+ 122 30.9
Sex
 Male 45 11.4
 Female 349 88.6
Educational status
 No education 254 64.5
 Primary 88 22.3
 Middle/JSS 39 9.9
 Secondary 11 2.8
 Tertiary/higher 2 0.5
Religion
 Traditional 93 23.6
 Christian 270 68.5
 Muslim 24 6.1
 Other 7 1.8
Ethnicity
 Kassem 171 43.4
 Nankam 200 50.8
 Buli 17 4.3
 Other 6 1.5
Marital status
 Never married 5 1.3
 Married/living 340 86.3
 Together 9 2.3
 Devoiced 39 9.9
 Windowed 1 0.2
Main occupation
 Subsistence farmer 238 60.4
 Trader 141 35.8
 Housewife 3 0.8
 Civil/public servant 4 1.0
 Unemployed 2 0.5
 Other 6 1.5
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care of themselves and their children which to them was 
achieved. The views of parents are exemplified in these 
quotes below:
R: “Yes I had in mind that VAST was going to pay 
for all the drugs or treatment at the hospital for me 
which they did. …so if you are recruited by VAST 
into their studies, they will pay for all the treatment 
for you and they will even treat your child to get 
well and that is why you have to be part of it” (IDI-
41 year old Mother).
Q: And do you normally get the good health?
R: “of course very well, when my child took part in 
that study, he has never had that type of sickness 
since then so because of that I have seen that it is 
beneficial to me” (IDI-41 year old Mother).
Attitude and trust towards the conduct of new drug trials
The results showed that majority 95.9 % (378) of the par-
ents were more than willing to allow their children to be 
enrolled in future clinical trials (Table 2).
Most of the parents 77.4  % (305) were of the opinion 
that new drugs should be tested on human beings. On 
the contrary, about 22 % (85) of them reported that new 
drugs should not be tested on human beings. Interest-
ingly from the results, it is observed that the number of 
participants who said it is good for new drugs to be tested 
on human beings is by one less than those who said they 
would actually give permit for their children to be partic-
ipated in trial studies. Again, two people who could not 
tell whether trial drugs should be tested on human beings 
or not however said they would allow their children to 
participate in clinical trials (Table 2).
Similar sentiments were expressed in the qualitative 
interviews. Most of the parents said that they were com-
mitted and willing to cooperate and support the conduct 
of new drug trials. They reported that the artesunate trial 
and other trial conducted in the past had contributed 
immensely to improve community trust in the formal 
health system. Apparently, community members actively 
monitored the health progress of children recruited 
into the study. This coupled with positive feedback by 
mothers and caregivers to family and community mem-
bers bolstered the image of the trial and by extension 
the health system among community members. There-
fore, the positive impact of past clinical trials including 
the artesunate trial has made community members to 
have positive views and attitude towards the conduct of 
clinical trials in the study area. Participants offered these 
views about their attitude and trust towards the conduct 
of clinical trials.
“When you are usually recruited into a study and 
they give your child drugs, people in the community 
will always come around and ask, how is the child 
doing after taking the drug? And because the drug 
has worked well for you, you will tell them it is good 
it is improving my child’s health. Because of that 
work, people now patronize the hospital, when they 
are sick, they go there knowing very well that that is 
where they can be cured” (IDI-48 year old Mother).
“We trust the VAST workers because they suffer a 
lot for our sake, taking care of us and our children, 
is good. May God help them and make their work 
develop” (IDI-47 year old Mother).
Main factors motivating willingness to participate in trial 
studies
NHRC since its existence over 25 year ago has carried out 
quite a number of new drug trial studies in its research 
communities. The cooperation, support and the involve-
ment of community members in these trial studies has 
been tremendous. What has motivated parents and other 
community members’ high level of cooperation, support 
and trust to always participate in these trial studies over 
the years is discussed below.
Quality of health care services provided to trial participant
The results demonstrated that quality of health care ser-
vices offered to trial participants greatly influence their 
trust and willingness to participate in new drug trials. 
Study participants were made to compare health care 
services offered to clinical trials participants and those 
who were not recruited into clinical trial studies when 
they both met at the health facility. The results showed 
that 92.9 % (366) respondents said there were differences 
Table 2 Attitude and  trust towards  the conduct of  new 
drug trials
Variables N = 394 frequency Percentage
Wiliness to participate
 Yes 378 95.94
 No 5 1.27
 Don’t know 11 2.79
Trial drugs test on human beings
 Yes 305 77.4
 No 85 21.6
 Don’t know 4 1.02
New drug test on child
 Yes 304 77.2
 No 88 22.3
 Don’t know 2 0.5
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in the health care services offered to clinical trial patients 
and routine patients at the health facility level. Major-
ity of the parents in this study reported that trial stud-
ies participants received quality health care services as 
compared to their colleagues who were not recruited into 
these trials. The results further established that 90.8  % 
(357) and 94.4 % (371) of parents said that trial patients 
were given detail medical examination and promptness 
of care respectively unlike their colleague children who 
were not part of these trial studies (Table 3).
Similar views were expressed by parents in the qualita-
tive interviews. They perceived that clinical trials led to 
improvement of health care services especially those who 
were recruited into these trial studies compared with 
routine patients when they both met at the health facility. 
Most of them reported that clinical trial patients received 
quicker and faster care and they were not allow to join 
long queues and as a result spent shorter time at the 
health facility as compared to routine patients. Staff were 
more patient towards trial patients, review their medical 
history and follow-ups monitoring visits were made by 
trial staff to ensure that study children were very healthy 
following treatment given them at the health facility. The 
following expressions reflect views on quality of health 
care services offered to trial participants.
“When you are referred there by the VAST people 
they would take good care of you quickly than when 
you go there alone for routine care. The reason is 
that I was having a child who was part of a one year 
study and when the child was sick, I took him there 
and when I got there the vast workers took the child 
quickly and sent him to the doctor for treatment. 
When the study was over and the child was not part 
of it again, we went to the hospital and we had to 
go and join the queue before we could see the doc-
tor unlike the first one where they just took the child 
straight from me to the doctor for examination. So to 
me, if you are part of a study the care is faster than 
the routine care” (IDI-39 year old Mother).
“During the time my child was a study child, any 
time he fell sick, the vast workers came and took him 
away for treatment. If a child is not a study child 
and falls sick, the mother would put him on her 
back, walk and by the time she gets to the hospital, 
there would be a crowd there. Your child is not the 
only patient and if you do not know anyone there, 
they will not attend to you, you have to do “wahala 
paa” (suffer a lot) before you may get to see the doc-
tor. But with the coming of the study, the vast work-
ers work for everyone, rich or poor. They only want to 
save humanity so they pick you there for treatment. 
It was better when the study was running” (IDI-
44 year old father).
Quantity, quality and cost of medications
Most of the respondents 90.9  % (358) said that clinical 
trials children received more drugs at the health facility 
than those whose children were not recruited into these 
trial studies. Only few respondents 0.76  % (20) thought 
otherwise. Similarly, most respondents 91.9  % (362) 
reported that drugs given to clinical trial children were 
of better quality and more effective than those given dur-
ing routine care. With regard to the cost of medications, 
most participants 96.9  % (378) said that drugs given to 
clinical trial children were less expensive (Table 3).
Findings were affirmed during the qualitative inter-
views where in-depth explanations were given on the 
basis of the suspicion that drugs given during clinical tri-
als were of better quality than those given during routine 
services. Parents pointed a practice in the routine care 
Table 3 Quality of health care services to trial participants
Variables N = 394 frequency Percentage
Differences in health care
 Yes 366 92.9
 No 20 5.1
 Don’t know 8 2.0
Quantity of drugs
 More drugs for participants 358 90.9
 More drugs for routine patients 3 0.8
 Same drugs for all 20 5.1
 Don’t know 13 3.3
Quality of drugs
 Quality drugs for participants 362 91.9
 Quality drugs for routine patients 5 1.3
 Same quality drugs for all 15 3.8
 Don’t know 12 3.1
Promptness of care
 Trials participants 371 94.4
 Routine participants 4 1.0
 No difference 11 2.8
 Don’t know 7 1.9
Detail examination
 Trial participants 357 90.8
 Routine participants 4 1.0
 No difference 22 5.6
 Don’t know 10 2.5
Cost of drugs/medicine
 Less cost for participants 378 96.9
 Less cost for routine patients 0 0.0
 No difference in cost 7 1.79
 Don’t know 5 1.28
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where health workers poured medicines from contain-
ers into bottles for patients and in the process “reduced 
the “strength” (efficacy) of the medicine”. Suspicions were 
also raised regarding the possibility of medicines being 
diluted with lots of water. In contrast, trial patients were 
mostly served with pre-packed drugs which in the per-
spective of parents offered high efficacy hence facilitated 
their willingness to allow their children to take part in 
these trial studies.
The vast (refers to NHRC) people give us more drugs 
and quite apart from that their drugs are even of 
more quality than the hospital drugs. The reason is 
that at the hospital, they will only give you paracet-
amole and quinine which may not be what is needed 
to treat the illness. The way they also do with the 
bottle medicine is not good. They could take one bot-
tle and share it with two people and when they open 
it and pour the medicine in a different bottle, the 
effectiveness of the medicine reduces….The way they 
delay if it happens that your child sickness is very 
serious then of course you will go back home with a 
dead child (IDI-38 year old Mother).
If your child is not a study child, you will pay so 
much money; only two bottles of medicine and the 
amount of money they will ask you to pay, you will 
not know what to do. But when they recruited my 
child into the study, whenever I got there they gave 
us all the medicines; they gave us medicine to cool 
down his body when he had high temperature, medi-
cine for diarrhea and vomiting, everything and I did 
not pay even a pesewa. Those who were not part of 
the study paid so much without getting that quantity 
of medicines (IDI-47 year old Mother).
Disease prevention and good health
The results in the quantitative survey showed that major-
ity of the respondents 99.5 % (392) said that the conduct 
of clinical trials had tremendously reduced the frequency 
of disease occurrences in the communities. With regards 
to malaria prevention, 98.5  % (388) of the parents said 
that the conduct of clinical trials had led to a drastic 
reduction in the prevalence of malaria in the study area. 
In the same way, 93.1 % (367) of them reported that the 
conduct of clinical trial had led to a reduction in deaths 
(Table 4).
It was observed in the qualitative interviews that these 
trials had helped to improve health of their children. 
Parents were of the view that in the past, there used 
to be many “strange diseases” that killed people espe-
cially children in their communities. They held a strong 
believe that due to the research activities of NHRC, most 
of these diseases have been eradicated. Most of them 
believed that it was as a result of clinical trials includ-
ing the artesunate trial conducted by the NHRC in the 
past that had resulted in the eradication of diseases 
such as measles and convulsion in their communities. 
They explained that the prevalence of certain diseases 
such as malaria, cerebrospinal meningitis, elephantiasis, 
cholera and diarrhoea have declined due to good health 
care services offered to them by health workers who 
work directly or indirectly in these trial studies. View 
expressed in the discussions suggested that the conduct 
of clinical trials have contributed to reduce infant mor-
tality in the study area. Parents expressed their views 
this way on the issue:
“The benefits are the way they cure the sicknesses. 
If not for their medicine how was one going to carry 
his/her child all the way to the hospital, you may get 
there and it would be too late but for the sake of that 
drug that they put into the child’s anus before you 
send the child to hospital is the reason why I am say-
ing that their work is good. Let me compare it with 
those of us they recruited our children. I must say 
that the drug is good because it has helped our chil-
dren to be healthy. We are better than those they did 
not recruit their children…”(IDI-40 year old Mother).
Table 4 Prevention of  Diseases, deaths and  living stand-
ards of trial participants
Variables N = 394 frequency Percentage
Reduce frequency of diseases
 Yes 392 99.5
 No 2 0.5
Reduce frequency of deaths
 Yes 367 93.1
 No 23 5.9
 Don’t know 4 1.0
Malaria prevention
 Yes 388 98.5
 No 5 1.3
 Don’t know 1 0.3
Improve living standards
 Yes 373 96.1
 No 14 3.6
 Don’t know 1 0.3
How living standard improved
 Refund 54 13.9
 Free medical care 97 25.0
 Improve child health 225 58.9
 Employment 2 0.5
 Other 16 1.7
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“Before the Artesunate trial, childhood diseases were 
so many; but with the coming of the trial the diseases 
have reduced. Only children who are destined to die 
fall sick these days. At first diseases like “kachuwa” 
(measles), chicken pox and “weyusunga” (convulsion) 
were common but the study brought so many medi-
cines for children, so the diseases that used to worry 
them have reduced” (IDI-34 year old Mother).
Trials influence on living standards of trial participants
The findings showed that 96.1 % (373) of the respondents 
said that the conduct of trials had greatly improved their 
living standards because of their involvement in these 
studies (Table 4).
Almost all the parents in the qualitative interviews 
were of the opinion that trial studies had contributed 
immensely to improving their living standards. They 
explained that the free medical care offered by these tri-
als, enables them save money which was used to buy food 
and other household items for the up keep of the family 
members. It also enables them to save money to educate 
their children who after completion of their studies got 
employed in other sectors which have helped to reduce 
the level of poverty and improved their living standards. 
In the words of one participant:
“Yes the studies have helped in this regard. You know 
that ill health is usually what makes people unable 
to work but once people are healthy, they are able to 
do their work to better their life” (IDI- trial partici-
pant’s parent).
Perceptions on exposure to risks during clinical trials
Few of the parents in the qualitative interviews however, 
highlighted some issues they did not like when their chil-
dren took part in these trial studies. They held the view 
that taking of blood samples from sick children was pain-
ful and has made the children to cry. They added that 
children with low hemoglobin, researchers’ still took 
blood samples from them. A female parent shared her 
views this way on the issue:
Q: What problems or risks did your child get in the 
trial study you took part?
R: You always think that, “oh, this child is sick and 
yet they are taking his/her blood; his blood is not 
much” but what can you do?….(IDI-39  year old 
Mother).
Adverse effect was also reported by few of the parents 
in the in-depth interviews. They mentioned burning 
of triode as a result of the use of new drugs as the main 
side effect trial participants were likely to experience. A 
48  year old parent expressed his views this way on the 
issue:
“Yes there are risks because you test and the results 
are positive, you test and the results are negative 
and so there is a risk there but you cannot actually 
succeed in life without taking risks. Let’s say that this 
drug is taken orally, it can burn your triode when 
you are taking it and the intestines can be destroyed 
and you can be sorry and these are some of the risks 
involved” (IDI with 48 year old father).
Discussion
Attitude and trust towards the conduct of new drug trials
People in the study districts continue to have so much 
trust in the conduct of new drug trials. The results 
showed high level of trust and positive attitude towards 
the conduct of clinical trials by stakeholders and other 
community members particularly parents whose children 
were recruited into the artesunate trial and other tri-
als conducted in the by the NHRC. Most of the parents 
reported that they are more than willing to be involved 
in future clinical trials. This is because of the positive 
impact and the numerous benefits people continue to get 
from their participation in these trial studies. This was 
further affirmed by the finding that a significant number 
of participants were willing to participate in clinical trial 
studies [2, 17]. People are willingness and ready to par-
ticipate in trial studies because it would help researchers 
to come out with new drugs to benefit their families and 
relatives [3, 4, 18].
Parents’ willingness, attitude and trust towards the con-
duct of new drug trials in our study have been high. Most 
of the parents said that they are committed and willing 
to cooperate and support the conduct of new drug tri-
als. This support and cooperation has been attributed to 
the initial trials conducted in the communities by NHRC 
including the artesunate trial which made huge impact on 
the lives of community members. For instance, the term 
VAST has become synonymous with the research centre 
largely owing to the fact that it was the first trial in this 
district but also because the trial achieved good results 
and the community members could easily still remember 
the trial [12].
Quality of care and medications
Better quality of care given to trials patients as compared 
to routine patients at the health facility level is said to be 
a strong motivation for parents to allow their children 
to be enrolled into new drug trials. The findings showed 
that trial patients receive better attention, promptness of 
care and quality medicine. An interesting observation in 
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the qualitative discussions is the association of packag-
ing of drugs to trial participants where pre-parked drugs 
are mostly given to them. They said this makes the drug 
very effective. The use of water to mix and serve drugs 
from big containers into smaller bottles at dispensa-
ries to routine patients is associated with weak efficacy. 
It is believed that the use of water to mix drugs and the 
process of pouring drugs into small bottles weakens the 
strength and effectiveness of the drug. Of course observ-
ing good hygienic practices in the dispensation of drugs 
would avoid contamination and ensure good quality 
drugs. The cost of treatment for patients involve in trial 
studies is lower than that of the routine patients. Most of 
the parents reported that their children had good health 
when they took part in the trial studies because of the 
quality of medicines they receive [2, 3].
A good relationship between researches and commu-
nities in which research studies are conducted is essen-
tial for successful conduct of trials studies. The extent to 
which trials are beneficial or perceived to be beneficial by 
participants influences the level of community coopera-
tion and support towards the conduct of these trial stud-
ies. Irrespective of whatever benefits a trial portends, it is 
important that in the mind’s eye of members of the com-
munity and parents, the trial should be seen as beneficial. 
Almost all the parents who were part of this study said 
that these trials are very useful and beneficial to them 
and their children in so many ways.
The results established that about 79  % (310) of 
respondents mentioned good health for them and 
their children as the main benefit they get when their 
children took part in these trial studies. In the qualita-
tive discussions, most parents mentioned free medical 
care, health education, prompt and appropriate medical 
attention to ensure good health for their children as the 
main motivation factor for their involvement in these 
trial studies [18]. These benefits are in line with expec-
tations of parents prior to their children involvement in 
the trial studies. Our results collaborate with findings 
from earlier studies that reported that trials participants 
were given free medical care [2–4]. Free health insur-
ance registration for study participants has also been 
reported one of the benefits for being involved in new 
drug trials [3, 11]. Our study setting is largely rural and 
poor but it is not clear that material benefits attract par-
ents to allow their children to take part in these trials. 
What is however clear is the placement of high pre-
mium on the quality of health care received during the 
conduct of these trials. This is directly in line with what 
parents and other community members would usually 
expect before taking the decision to be involved in these 
trial studies [2, 3].
Disease prevention
Closely related to the benefits trial studies bring to trial 
participants, there is the strong tendency that trial stud-
ies would help to reduce the occurrence of diseases at the 
community level. The qualitative findings showed that 
trial studies have contributed immensely in reducing dis-
ease occurrences and even help to eradicate certain dis-
eases at the community level. Diseases like measles and 
convulsion have been eradicated while the rate at which 
people are infected by malaria, cerebrospinal menin-
gitis, cholera, elephantiasis and diarrhoea especially in 
children have been reduced. This was attributed to the 
efforts of the NHRC. While acknowledging the impor-
tant role of NHRC in health promotion in the study area, 
parents appear to have an exaggerated perception of its 
contribution with the neglect of efforts made by the for-
mal health system in this regard. For instance, the NHRC 
has not played a major role in the eradication of measles 
yet the Centre is easily credited with such achievement. 
This strong perception by parents has made them to 
develop so much trust to the activities of the centre and 
this motivates them to participate fully in the activities of 
the research centre including the conduct of these trial 
studies. The results showed that about 99  % of parents 
said that the conduct of trial studies has helped to reduce 
the prevalence of malaria in the study area. It is reported 
that the conduct of clinical trials is effective in prevent-
ing disease like diarrhoea, preventing complications and 
reduced hospital attendance [1].
Purported reductions in disease occurrence, free medi-
cal care and the other benefits people get from partici-
pating in the conduct of trial studies, promotes savings 
for other household needs and this has affected their liv-
ing standard positively hence explains why they are will-
ing to be involved in the conduct of these new drug trial 
studies.
Clinical trial participants in this setting are exposed 
to some disadvantages or risks for their involvement in 
new drug trials. A particular concern is the crying of chil-
dren during samples taking and likely side effects of new 
drugs such as burning of triode and intestines. It is dem-
onstrated that uncertainty in the efficacy of new drugs 
and side effects of new drugs may have on the liver and 
kidney as serious risk to trial participants [3, 5, 11]. It is 
therefore important that clinical trials in this and simi-
lar settings ensure full disclosure of information includ-
ing anticipated risks, benefits and trial procedures [3]. 
Most of the parents who took part in this study however, 
expressed strong belief and trust in the efficacy of study 
drugs used in this setting. Apparently, this trust is based 
on long history of good relationship in the conduct of 
research by the NHRC over the years in the communities.
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Conclusion
It is necessary to highlight the crucial role played by 
stakeholders and other community members in the con-
duct of clinical trials in this setting over the years. There 
are certain factors that motivate community members’ 
trust and willingness to offer themselves available to be 
use in new drug trials. These include free medical care, 
quality and availability of health care services, improve 
health status, disease prevention among others. Gener-
ally, the implementation of clinical trials in the Kassena-
Nankana districts is believed to have positive impact on 
health status of people particularly those who partici-
pated directly in these trials.
Despite the fact that all these benefits are being enjoyed 
by community members as a result of the conduct of 
clinical trials in communities, certain issues have been 
raised by parents such as the safety, likely risks and side 
effects of new drugs. It is therefore recommended that 
pragmatic steps be taken by researchers to address the 
few concerns raised by the stakeholders on the conduct 
of clinical trials. This will help improve and sustain the 
kind of trust community members have built over the 
years towards the conduct of clinical trials. This will help 
strengthening their relationship with researchers and 
consequently encourage communities continue support 
and involvement in the conduct of clinical trial studies.
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